Janssen seeks FDA approval for its antipsychotic drug to treat schizophrenia
Janssen Research & Development has submitted a new drug application (NDA) for its three-month atypical antipsychotic paliperidone palmitate to the US Food and Drug Administration (FDA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Invega | Invega Sustenna | New Drug Applications | Pharmaceuticals | Schizophrenia